UoH startup partners with GenepowerRx to personalize medical procedures


Transcell Oncologics, an ASPIRE-TBI incubator at the University of Hyderabad (UoH), announced a partnership with GenepoweRx, a bioinformatics engine, in its workflow.

Transcell has developed a vertical “HEMATO” in the translation of adult stem cell technology as part of the hematopoietic stem cell transplantation procedure.

This merger allows Transcell to offer the prescription of HEMATO’s PREGEN genomic drugs for the management of any predisposition to disease or illnesses. These next-generation in-silico tools integrated into the HEMATO workflow provide solutions for health-conscious families and families with a history of illness to make informed, data-driven decisions, manage and care for their health.

HEMATO-powered solutions developed to provide customers with predictive and complete signatures of omic stem cells (PREGEN), cryo-archiving of enriched progenitors for tandem and transplants (HEMATOCRYO), cell therapies in approved hematopoietic stem cell transplantation (HSCT) procedures ) are valuable additions in disease treatment helping transplant specialists to personalize treatments.

GenepoweRx, developed by Dr. Kalyan Uppaluri and Dr. Hima Challa, clinicians practicing genomic medicine in Hyderabad and trained at Stanford and Harvard University respectively, is approved by Memorial Sloan Kettering Cancer Center (NY) to support personalization of treatment strategies targeted. K&H, a bespoke concept clinic, is run by them, offering a personalized plan for each of their patients, distilled from their unrivaled world-class experience practicing genomic medicine.

“With our constant focus on working in technology to enable the targeted client to benefit from regulated clinical practices, this working relationship with genomic medicine practitioners brings together innovation and execution customization technology to deliver services.” of superior quality, ”said Subhadra Dravida Ph. D., CEO and Founder of Transcell in a joint statement with Dr Vinayender Tulla, Director of Transcell.

“By combining bioinformatics tools, relevant downstream clinical practice expertise with Transcell’s validated cell technology, we are delighted to support their differentiated and meaningful offerings,” said Dr. Kalyan Uppalurisigning, the working relationship at Hyderabad.

Source link


Comments are closed.